Trial Profile

Effectiveness and safety of Vedolizumab in a large real-life cohort for the treatment of Inflammatory bowel disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vedolizumab (Primary)
Indications Crohn's disease; Ulcerative colitis
Focus Adverse reactions; Therapeutic Use
Acronyms IG-IBD LIVE; LIVE

Most Recent Events

09 May 2023 Status changed from recruiting to completed, as per Results preliminary analysis, presented at the Digestive Disease Week 2023
09 May 2023 Results preliminary analysis, presented at the Digestive Disease Week 2023
01 Jul 2022 Results assessing effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly Ulcerative Colitis and Crohn's Disease patients, published in the Alimentary Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com